Novartis’ PI Motion re Gilenya® Denied: Generic Entry Does Not Necessarily Cause “Catastrophic Damages” to the Brand

The Israeli Tax Authority has issued groundbreaking guidance on SAFE instruments, providing much-needed clarity for venture capital investments. Our client update explores the new safe harbor provisions, key compliance conditions, and practical implications for startups and investors navigating Israel’s evolving tax landscape. Essential reading for the venture ecosystem.